<DOC>
	<DOCNO>NCT02403505</DOCNO>
	<brief_summary>That current oncology drug USA market universal problem low effectiveness pharmacology cancer cell high risk toxicology normal cell demonstrate follow significantly reasonably : enough far oncology drug target directly like cancer patient-specific biomarkers ; must oncology drug target ' SNPs via patient-specific haplotype block like real personalized individualized cancer patient-specific biomarkers .</brief_summary>
	<brief_title>Discovery Stage Clinical Study About Oncology Drugs Single Nucleotide Polymorphisms</brief_title>
	<detailed_description>In Sponsor-Investigator 's discovery human subject ' study , investigator use ABIRATERONE plus PREDNISONE plus ENZALUTAMIDE ( 300 patient - Group 1 ) ABIRATERONE plus PREDNISONE plus NILANDRON ( 300 patient - Group 2 ) treat Prostate Cancer patient try look relationship ABIRATERONE ACETATE TABLET therapeutic efficacy drug target CYP17 SNP Genotyping via assay patient-specific haplotype block , relationship ABIRATERONE ACETATE TABLET therapeutic safety drug target CYP1A2 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4/5 , CYP17 SULT2A1 SNP Genotyping via assay patient-specific haplotype block . According ABIRATERONE ACETATE TABLET Labeling Directions , ABIRATERONE drug target CYP17 effectiveness-associated ; ABIRATERONE drug target CYP1A2 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4/5 , CYP17 SULT2A1 also risk-associated . The investigator hope discover CYP17 SNP Genotypes via patient-specific haplotype block may effectiveness-associated , CYP1A2 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4/5 , CYP17 SULT2A1 SNP Genotypes via patient-specific haplotype block may risk-associated .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Nilutamide</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Clinical diagnosis prostate cancer Clinical biopsy diagnosis prostate cancer Suitable local therapy surgery Random double blind Measurable disease Adequate organ function Adequate performance status Age 22 year old Sign inform consent form Treatment anticancer therapy stop currently Pregnancy Breastfeeding The patient serious intercurrent illness infectious disease Have one different kind cancer time Allergy drug Serious Bleed Tendency Serious Risks Serious Adverse Events drug product The prohibition drug product Up current label</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>SNP</keyword>
	<keyword>Single Nucleotide Polymorphism</keyword>
	<keyword>Genetics</keyword>
	<keyword>Pharmacogenomic</keyword>
	<keyword>Pharmacogenetic</keyword>
	<keyword>gene</keyword>
	<keyword>genome</keyword>
	<keyword>genotype</keyword>
	<keyword>genotyping</keyword>
	<keyword>Oncology</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Personalize</keyword>
	<keyword>Individualize</keyword>
</DOC>